Research and Development Update – Q4 2025

AI SummaryClose X

Solvonis Therapeutics plc provided a Q4 2025 research and development update, highlighting progress in addiction and psychiatry with multiple anticipated catalysts in 2026. The lead program, SVN-001 for severe alcohol use disorder, is in a Phase 3 trial with top-line results expected late 2027 or early 2028. SVN-002, an oral esketamine thin-film for moderate-to-severe AUD, is progressing with pharmacokinetic bridging expected in Q1 2026, aiming for a US FDA Phase 2b trial. SVN-015, a novel compound for stimulant use disorder, was accepted into NIDA's Addiction Treatment Discovery Program, with initial results expected in Q1 2026. The SVN-SDN-14 program for PTSD is advancing through in-vivo studies, with lead-candidate selection anticipated in Q1 2026. The company's AI-enabled discovery platform continues to generate novel CNS candidates.

Disclaimer*

UK 100

Latest directors dealings